The U.S. Supreme Court’s unexpected decision to take up a Texas voting case poses perhaps the most acute threat in a generation to Latino political strength in California. But how much of the threat actually materializes is decidedly less known.
Drug manufacturers will be required to fund and manage medication disposal programs, following the US Supreme Court’s decision to not hear the pharmaceutical industry’s case against a drug take-back law in California. The Pharmaceutical...Show More Summary
The LA Times reports. … Continue reading ?
In recent years, California voters have backed a series of changes to the state's elections system to reshape its political landscape. Now, potential upheaval is brewing again, this time from the U.S. Supreme Court.
California political analyst Tony Quinn has been following redistricting matters long enough to remember when the Earl Warren court handed down its "one person, one vote" ruling half a century ago.
The Supreme Court declines to hear a case challenging a drug-disposal law, but another California law governing out-of-state art sales is struck down.
David Savage reports for the LA Times. See also Melanie Mason’s, “Could U.S. Supreme Court Shrink California’s Congressional Clout?” … Continue reading ?
The U.S. Supreme Court's agreement Tuesday to hear a case that could potentially overhaul how political districts are drawn has sparked waves of speculation among political and legal wonks -- including questions as to how a ruling could affect California's clout in Congress.
In a setback to drug makers, the U.S. Supreme Court denied an industry request to review a lawsuit filed over a drug take-back program in Alameda County, California.
It was good news for California drivers when the state Supreme Court moved last week to end a requirement that people pay traffic tickets before being allowed to contest them.
The Supreme Court mulls a case challenging a California law that requires out-of-state drug companies to fund a local disposal program.
By Dave Kranz, agalert.com A sweeping state appellate court decision, ruling part of the California Agricultural Labor Relations Act unconstitutional, sets the stage for an eventual state Supreme Court decision on the act's mandatory mediation and conciliation provisions.
That raises the possibility of later disclosure of the information, retaliation against donors, or both; whether it’s unusual enough for the U.S. Supreme Court to step in to stop it remains to be seen. Harris’s target and adversary in...Show More Summary
Supreme Court Justice Anthony M. Kennedy dealt a speedy setback Monday to conservative advocacy groups that had sought to shield the names of their major donors in California.
David Savage reports for the LAT. … Continue reading ?
A conservative group based in Virginia that fights for free speech and free spending in politics is asking the U.S. Supreme Court to block California Atty. Gen. Kamala Harris from seeing its list of major donors.
SMOKING OUT CONSERVATIVE DONORS: The Center for Competitive Politics–a conservative-leaning supporter of free political speech–has petitioned the Supreme Court to stop California state Attorney General Kamala Harris from gaining access to its list of donors, contained in a Form 990 that is filed with the Internal Revenue Service (as part of its application for 501(c)(3) […]
Lyle Denniston: A Virginia-based political advocacy group asked the Supreme Court on Friday to bar state officials in California from gaining access to the lists of people who donate money or services to it. The Center for Competitive Politics, a vigorous supporter … Continue reading ?
For many years now, we've been talking about the problematic practice of "pay for delay" in the pharma industry. This involved patent holders paying generic pharmaceutical makers some amount of money to not enter the market in order to keep their own monopoly even longer. Show More Summary
The California Supreme Court on Thursday revived a class-action lawsuit that accuses Bayer AG of paying another drug company to delay introducing a generic version of a Bayer antibiotic.